Sarepta Therapeutics (SRPT) Ticks Higher as Humana Approves 100% Coverage

October 6, 2016 11:43 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Sarepta Therapeutics (NASDAQ: SRPT) ticked higher on reports Humana approved 100% coverage for recently-approved Exondys51, (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD).

Shares last traded up 0.6% to $62.72.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

FDA, Trader Talk

Add Your Comment